News Focus
News Focus
Followers 192
Posts 28789
Boards Moderated 13
Alias Born 04/03/2002

Re: None

Tuesday, 04/09/2024 1:13:28 PM

Tuesday, April 09, 2024 1:13:28 PM

Post# of 27732
$RENB - Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace | NASDAQ https://www.nasdaq.com/press-release/cutting-edge-ai-company-gedicube-and-cyclomics-sign-binding-loi-to-join-forces-and-0

From the article:

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
Cyclomics’ 4th generation liquid biopsy genomics platform is a truly “Omni-Omic” blood test ready for AI application
GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.
GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today